Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group
- 20 December 2016
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 83 (5) , 1097-1107
Abstract
Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR). Pharmacokinetic (PK) characterization of temsirolimus in children is limited and there is no paediatric temsirolimus population PK model available. The objective of this study was to simultaneously characterize the PK of temsirolimus and its metabolite sirolimus in paediatric patients with recurrent solid or central nervous system tumours and to develop a population PK model. The PK data for temsirolimus and sirolimus were collected as a part of a Children's Oncology Group phase I clinical trial in paediatric patients with recurrent solid tumours. Serial blood concentrations obtained from 19 patients participating in the PK portion of the study were used for the analysis. Population PK analysis was performed by nonlinear mixed effect modelling using NONMEM. A three-compartment model with zero-order infusion was found to best describe temsirolimus PK. Allometrically scaled body weight was included in the model to account for body size differences. Temsirolimus dose was identified as a significant covariate on clearance. A sirolimus metabolite formation model was developed and integrated with the temsirolimus model. A two-compartment structure model adequately described the sirolimus data. This study is the first to describe a population PK model of temsirolimus combined with sirolimus formation and disposition in paediatric patients. The developed model will facilitate PK model-based dose individualization of temsirolimus and the design of future clinical studies in children.Keywords
Funding Information
- Uehara Memorial Foundation
- Japan Research Foundation for Clinical Pharmacology
This publication has 40 references indexed in Scilit:
- A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumorsInvestigational New Drugs, 2013
- Development of a Physiologically‐Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A ContentCPT: Pharmacometrics & Systems Pharmacology, 2013
- A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinomaOral Oncology, 2013
- Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)Clinical Cancer Research, 2012
- Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcomaEuropean Journal of Cancer, 2012
- Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumorsInvestigational New Drugs, 2011
- Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid TumorsJournal of Clinical Oncology, 2011
- A phase 2 study of temsirolimus (CCI‐779) in patients with soft tissue sarcomasCancer, 2011
- Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II ConsortiumJournal of Clinical Oncology, 2010
- FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell CarcinomaThe Oncologist, 2010